LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants

Phase 1, randomised, double-blind trial of naperiglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started May 2025; status: completed.